+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Premenstrual Syndrome Treatment Market Report by Drug Type, Type, Distribution Channel, and Region 2024-2032

  • PDF Icon

    Report

  • 149 Pages
  • August 2024
  • Region: Global
  • IMARC Group
  • ID: 5911999
The global premenstrual syndrome treatment market size reached US$ 1.39 billion in 2023. Looking forward, the publisher expects the market to reach US$ 1.89 billion by 2032, exhibiting a growth rate (CAGR) of 3.42% during 2023-2032. The market is driven by the growing focus on precision medicine, as it enhances patient outcomes and treatment efficiency, rising healthcare spending, which improves access to care and expands treatment options, and increasing female workforce participation.

Premenstrual Syndrome Treatment Market Analysis:

  • Major Market Drivers: The growing demand for precision medicine, along with the rising healthcare expenditure, is positively influencing the market.
  • Key Market Trends: Increasing female workforce participation and ongoing technological advancements are stimulating the growth of the market.
  • Geographical Trends: North America holds the largest segment because of its strong healthcare infrastructure and robust economy, which leads to greater affordability of medications.
  • Competitive Landscape: Some of the major market players in the premenstrual syndrome treatment industry include AbbVie Inc., BASF SE, Bayer AG, Dr. Reddy’s Laboratories Ltd, Eli Lilly and Company, GlaxoSmithKline Plc., H. Lundbeck A/S, Pfizer Inc., SHIONOGI & Co. Ltd., among many others.
  • Challenges and Opportunities: While the market faces challenges like lack of awareness and understanding about PMS, it also encounters opportunities in the development of new treatment options.

Premenstrual Syndrome Treatment Market Trends:

Growing focus on precision medicine

As per the publisher's report, the global precision medicine market reached US$ 75.2 Billion in 2023. Precision medicine can deliver medical interventions that are tailored as per patient characteristics including genetic profile, hormone status, and symptoms. In the context of PMS, it can vary widely in terms of symptoms and severity among individuals, personalized approaches allow for more targeted and effective treatments.

Furthermore, genetic factors or biomarkers that are linked to PMS help in tailoring treatment options to be most effective for each patient. This is leading to improved outcomes and lesser trial and error in treatment options. Apart from this, by selecting medications that are less likely to cause an adverse reaction by matching patients with treatments based on their genetic or physiological profiles is expanding the market growth.

Rising healthcare spending

As healthcare expenditure is increasing, more people, including women troubled with PMS, are able to seek medical help, including primary care physicians, gynecologists and other practitioners who may diagnose and treat PMS appropriately. In addition, high healthcare spending often found to be associated with higher access to other treatment options of PMS, which includes pharmacological treatment like hormonal therapies, antidepressants, and non-pharmacological therapies like cognitive behavioral therapy or lifestyle modifications. High healthcare expenditure is creating more opportunities for R&D activities that can help find better PMS therapies. According to the content updated in 2024 on the website of the Centers for Medicare & Medicaid Services, the healthcare spending share of GDP is forecasted to grow from 17.3% in 2022 to 19.7% in 2032.

Increasing female workforce participation

As per the World Bank, female labor force participation rates were 49% worldwide in 2023. As more women are entering the workforce, the economic implications of PMS are becoming more apparent. This poses a threat to productivity, attendance and performance at work due to its symptoms. Recognizing these impacts, employers and healthcare providers are more motivated to find effective treatments that can help reduce the workplace disruptions caused by PMS. In addition, companies are investing in workplace wellness programs that include support for reproductive health issues like PMS. These programs offer access to therapies, flexible scheduling around symptomatic days, and educational resources, all of which increase awareness and use of available PMS treatments.

Premenstrual Syndrome Treatment Market Segmentation:

The publisher provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on drug type, type, and distribution channel.

Breakup by Drug Type:

  • Analgesics
  • Antidepressants
  • Oral Contraceptives and Ovarian Suppression Agents
  • Others

Analgesics accounts for the majority of the market share


Premenstrual syndrome refers to several symptoms that are physical and psychological in nature and which affect many women prior to menstrual cycles, such as abdominal pain, headaches, and muscular pain. Analgesics are widely preferred as they provide quick relief from these symptoms, making them a go-to choose for many women looking immediate comfort during their menstrual cycles. In addition, people are getting aware about their efficiency in controlling pain, which is driving the demand for analgesics in the PMS treatment market.

Breakup by Type:

  • Prescription
  • Over-the-Counter

Over-the-counter holds the largest share of the industry


Over-the-counter (OTC) products for PMS include pain relievers, diuretics, and other supplements like calcium and magnesium that one can be purchased on the counter without the prescription of doctor. This accessibility allows women treat symptoms independently without having to see a doctor. Bloating, cramping, fatigue, and mood swings are becoming serious problems as a result of PMS. OTC medicines offer numerous solutions to these issues as per different symptoms. The familiarity of OTC brands and the ease of purchasing these products from pharmacies, retail stores, and online platforms is contributing to the market growth.

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Stores

Drugs stores and retail pharmacies represent the leading market segment


Women are preferring drug stores and pharmacies as they can get a wide range of OTC medications and supplements to alleviate PMS symptoms. This ensures that those women suffering from PMS can get relief in the quickest way possible without the need for a prescription. . Secondly, drug stores and retail pharmacies offer customers a wide diversity of brands and forms of products which can help them select the required products according to their needs and symptoms. This variety enhances individual satisfaction and ensures that people can find products tailored as per their specific needs.

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

North America leads the market, accounting for the largest premenstrual syndrome treatment market share


As per an article published on the website of Canadian Institute for Health Information, Canada health care spending reached $344 billion in 2023. As healthcare expenditures is rising, there is a corresponding increase in the availability of specialized healthcare services and resources dedicated to the health of women, including PMS. This includes improved access to healthcare professionals who can diagnose and treat PMS effectively, leading to greater awareness and recognition of the condition among patients. Moreover, North America has a high prevalence of PMS cases, which prompts a significant demand for effective treatment solutions. In addition, the strong economy of the region, leading to the greater affordability of healthcare services and medications, further driving the market growth.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the premenstrual syndrome treatment industry include AbbVie Inc., BASF SE, Bayer AG, Dr. Reddy’s Laboratories Ltd, Eli Lilly and Company, GlaxoSmithKline Plc., H. Lundbeck A/S, Pfizer Inc. and SHIONOGI & Co. Ltd.
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
  • Key players are developing and introducing new medications and treatments for managing PMS symptoms, expanding treatment choices for patients. They are conducting research and participating in clinical trials to better understand PMS mechanisms, validate treatment efficacy, and explore new therapeutic approaches. Moreover, many companies are focusing on personalized medicine approaches to tailor treatments based on individual patient characteristics, improving treatment outcomes and patient satisfaction. Key players are involved in advocacy efforts to raise awareness about PMS, improve diagnosis rates, and educate healthcare providers and patients about available treatment options. They are focusing on integrating digital health technologies, such as apps for symptom tracking, wearable devices, and telemedicine solutions, to enhance patient care and treatment outcome. For instance, in 2024, Samphire Neuroscience startup raised $2.3M to tackle PMS and period pain using neurotechnology wearable.

Premenstrual Syndrome Treatment Market News:

  • September 12, 2023: Vistagen, a late clinical-stage biopharmaceutical company announced positive results from exploratory phase 2A study of PH80 for acute management of the symptoms of premenstrual dysphoric disorder (PMDD), including negative mood and physical and behavioral symptoms.

Key Questions Answered in This Report

1. What was the size of the global premenstrual syndrome treatment market in 2023?
2. What is the expected growth rate of the global premenstrual syndrome treatment market during 2024-2032?
3. What are the key factors driving the global premenstrual syndrome treatment market?
4. What has been the impact of COVID-19 on the global premenstrual syndrome treatment market?
5. What is the breakup of the global premenstrual syndrome treatment market based on the drug type?
6. What is the breakup of the global premenstrual syndrome treatment market based on the type?
7. What is the breakup of the global premenstrual syndrome treatment market based on the distribution channel?
8. What are the key regions in the global premenstrual syndrome treatment market?
9. Who are the key players/companies in the global premenstrual syndrome treatment market?

Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Premenstrual Syndrome Treatment Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug Type
6.1 Analgesics
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Antidepressants
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Oral Contraceptives and Ovarian Suppression Agents
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Others
6.4.1 Market Trends
6.4.2 Market Forecast
7 Market Breakup by Type
7.1 Prescription
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Over-the-Counter
7.2.1 Market Trends
7.2.2 Market Forecast
8 Market Breakup by Distribution Channel
8.1 Hospital Pharmacies
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Drug Stores and Retail Pharmacies
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Online Stores
8.3.1 Market Trends
8.3.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 AbbVie Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 BASF SE
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Bayer AG
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Dr. Reddy’s Laboratories Ltd
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.5 Eli Lilly and Company
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 GlaxoSmithKline Plc.
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
14.3.7 H. Lundbeck A/S
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.7.4 SWOT Analysis
14.3.8 Pfizer Inc.
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis
14.3.9 SHIONOGI & Co. Ltd.
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 Financials
14.3.9.4 SWOT Analysis
List of Figures
Figure 1: Global: Premenstrual Syndrome Treatment Market: Major Drivers and Challenges
Figure 2: Global: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018-2023
Figure 3: Global: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 4: Global: Premenstrual Syndrome Treatment Market: Breakup by Drug Type (in %), 2023
Figure 5: Global: Premenstrual Syndrome Treatment Market: Breakup by Type (in %), 2023
Figure 6: Global: Premenstrual Syndrome Treatment Market: Breakup by Distribution Channel (in %), 2023
Figure 7: Global: Premenstrual Syndrome Treatment Market: Breakup by Region (in %), 2023
Figure 8: Global: Premenstrual Syndrome Treatment (Analgesics) Market: Sales Value (in Million US$), 2018 & 2023
Figure 9: Global: Premenstrual Syndrome Treatment (Analgesics) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 10: Global: Premenstrual Syndrome Treatment (Antidepressants) Market: Sales Value (in Million US$), 2018 & 2023
Figure 11: Global: Premenstrual Syndrome Treatment (Antidepressants) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 12: Global: Premenstrual Syndrome Treatment (Oral Contraceptives and Ovarian Suppression Agents) Market: Sales Value (in Million US$), 2018 & 2023
Figure 13: Global: Premenstrual Syndrome Treatment (Oral Contraceptives and Ovarian Suppression Agents) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 14: Global: Premenstrual Syndrome Treatment (Other Drug Types) Market: Sales Value (in Million US$), 2018 & 2023
Figure 15: Global: Premenstrual Syndrome Treatment (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 16: Global: Premenstrual Syndrome Treatment (Prescription) Market: Sales Value (in Million US$), 2018 & 2023
Figure 17: Global: Premenstrual Syndrome Treatment (Prescription) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 18: Global: Premenstrual Syndrome Treatment (Over-the-Counter) Market: Sales Value (in Million US$), 2018 & 2023
Figure 19: Global: Premenstrual Syndrome Treatment (Over-the-Counter) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 20: Global: Premenstrual Syndrome Treatment (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 21: Global: Premenstrual Syndrome Treatment (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 22: Global: Premenstrual Syndrome Treatment (Drug Stores and Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 23: Global: Premenstrual Syndrome Treatment (Drug Stores and Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 24: Global: Premenstrual Syndrome Treatment (Online Stores) Market: Sales Value (in Million US$), 2018 & 2023
Figure 25: Global: Premenstrual Syndrome Treatment (Online Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 26: North America: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 27: North America: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 28: United States: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 29: United States: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 30: Canada: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 31: Canada: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 32: Asia-Pacific: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 33: Asia-Pacific: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 34: China: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 35: China: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 36: Japan: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 37: Japan: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 38: India: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 39: India: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 40: South Korea: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 41: South Korea: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 42: Australia: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 43: Australia: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 44: Indonesia: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 45: Indonesia: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 46: Others: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 47: Others: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 48: Europe: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 49: Europe: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 50: Germany: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 51: Germany: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 52: France: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 53: France: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 54: United Kingdom: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 55: United Kingdom: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 56: Italy: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 57: Italy: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 58: Spain: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 59: Spain: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 60: Russia: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 61: Russia: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 62: Others: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 63: Others: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 64: Latin America: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 65: Latin America: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 66: Brazil: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 67: Brazil: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 68: Mexico: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 69: Mexico: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 70: Others: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 71: Others: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 72: Middle East and Africa: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 73: Middle East and Africa: Premenstrual Syndrome Treatment Market: Breakup by Country (in %), 2023
Figure 74: Middle East and Africa: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 75: Global: Premenstrual Syndrome Treatment Industry: SWOT Analysis
Figure 76: Global: Premenstrual Syndrome Treatment Industry: Value Chain Analysis
Figure 77: Global: Premenstrual Syndrome Treatment Industry: Porter's Five Forces Analysis
List of Tables
Table 1: Global: Premenstrual Syndrome Treatment Market: Key Industry Highlights, 2023 and 2032
Table 2: Global: Premenstrual Syndrome Treatment Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
Table 3: Global: Premenstrual Syndrome Treatment Market Forecast: Breakup by Type (in Million US$), 2024-2032
Table 4: Global: Premenstrual Syndrome Treatment Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
Table 5: Global: Premenstrual Syndrome Treatment Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 6: Global: Premenstrual Syndrome Treatment Market: Competitive Structure
Table 7: Global: Premenstrual Syndrome Treatment Market: Key Players

Companies Mentioned

  • AbbVie Inc.
  • BASF SE
  • Bayer AG
  • Dr. Reddy’s Laboratories Ltd
  • Eli Lilly
  • Company
  • GlaxoSmithKline Plc.
  • H. Lundbeck A/S
  • Pfizer Inc.
  • SHIONOGI & Co. Ltd.

Methodology

Loading
LOADING...

Table Information